Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Oral Cavity Cancer Clinical Trials

A listing of Oral Cavity Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (14) clinical trials

GDF15 Based TPF Induction Chemotherapy for OSCC Patients

Induction chemotherapy is regarded as an effective way to reduce or downgrade the locally advanced or aggressive cancers, and to improve the chance of eradication of the locoregional lesions by radical surgery and/or radiotherapy. However, there are still debates on the clinical value of induction chemotherapy for patients with advanced ...

Phase

uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer

To compare the diagnostic value of uPAR-PET/CT for prognostication compared to the current imaging options (CT, MRI and ultrasound) by observer-blinded readings. The reference that will be used as "gold standard" is the pathological examination of the surgically removed tissues. The new imaging modality (uPAR-PET/CT) will be used in two ...

Phase

Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage

Induction chemotherapy is regarded as an effective way to reduce or downgrade the locally advanced or aggressive cancers, and to improve the chance of eradication of the locoregional lesions by radical surgery and/or radiotherapy. However, there are still debates on the clinical value of induction chemotherapy for patients with advanced ...

Phase

Maintenance Tegafur-uracil in Resected Oral Cavity Cancer With ECS+

The primary endpoint will be 2-years distant failure rate which will be estimated by Kaplan-Meier method with two-sided 95% confidence interval. The secondary endpoints are described as follows: 2-year locoregional failure rate, 2-year PFS rate and 2-year OS rate will be estimated by Kaplan-Meier method with two-sided 95% confidence interval. ...

Phase

Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma

PRIMARY OBJECTIVES: I. To assess the efficacy of ficlatuzumab, with or without concurrent cetuximab, in patients with cetuximab-resistant, recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) as measured by progression-free survival (PFS). SECONDARY OBJECTIVES: I. To describe toxicity and patient-reported quality of life. II. To evaluate response rate and overall ...

Phase

Photodynamic Therapy With HPPH Compared to Standard of Care Surgery in Treating Patients With Oral Cavity Cancer

PRIMARY OBJECTIVES: I. To test the non-inferiority of photodynamic therapy (PDT) to standard of care surgery by comparing the rate of tumor response after PDT to those observed after surgery, at 24 months post treatment. SECONDARY OBJECTIVES: I. To determine quality of life (QoL) at 6, 12, 18 and 24 ...

Phase

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

PRIMARY OBJECTIVES: I. To evaluate the disease-free survival (DFS) of patients with stage III-IV squamous cell carcinoma of the head and neck (SCCHN) and disruptive p53 mutations after primary surgical resection followed by postoperative radiotherapy (PORT) alone or PORT with concurrent cisplatin. SECONDARY OBJECTIVES: I. To evaluate the DFS of ...

Phase

Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer

OCC patients who are scheduled for surgery will be given Nivolumab prior to surgery to see if there are any changes in surgical outcomes.

Phase

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Primary Objectives: To determine the clinical efficacy of pembrolizumab combined with cetuximab for patients with R/M HNSCC. Cohort 1 (PD-1/PD-L1 inhibitor-nave, cetuximab-nave): clinical efficacy defined as overall response rate. Cohort 2 (PD-1/PD-L1 inhibitor-refractory, cetuximab-nave): clinical efficacy defined as overall response rate. Cohort 3 (PD-1/PD-L1 inhibitor-refractory, cetuximab-refractory): clinical efficacy defined as ...

Phase

Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer

PRIMARY OBJECTIVE: To estimate the overall response rate (ORR) of patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN) who receive the combination of pembrolizumab and cabozantinib. SECONDARY OBJECTIVES: To estimate the progression-free survival (PFS) of patients treated with the combination of pembrolizumab and cabozantinib. To ...

Phase